Search
Research
Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103− and XCR1+CD103+ dendritic cellsThis report provides new insight into the functional specialization within the broad network of dendritic cells that are responsible for skin immunosurveillance
Research
Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.This study describes the development and molecular characterization of a panel of patient-derived infant leukemia oncogene xenografts and their sensitivity...
Research
Breastfeeding and nutrition to 2 years of age and risk of childhood acute lymphoblastic leukemia and brain tumorsAcute lymphoblastic leukemia and childhood brain tumors are 2 of the most common forms of childhood cancer, but little is known of their etiology.
Research
The Childhood Leukemia International ConsortiumThe Childhood Leukemia International Consortium (CLIC) was established in 2007 to promote investigations of rarer exposures, gene-environment interactions...
Research
Parental smoking and risk of childhood brain tumorsChildhood brain tumors (CBT) are the leading cause of cancer death in children, yet their etiology remains largely unknown.
Research
Parental alcohol consumption and risk of childhood acute lymphoblastic leukemia and brain tumorsChildhood acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and brain tumors (CBTs) are the leading cause of cancer death in...
Research
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63We hypothesized that reactivation of p53 by inhibition of its negative regulator will result in p53-mediated growth arrest and apoptosis.
Research
MEIS proteins as partners of the TLX1/HOX11 oncoproteinAberrant expression of the TLX1/HOX11 proto-oncogene is associated with a significant subset of T-cell acute lymphoblastic leukemias...
News & Events
Finding new treatments for rare brain cancers in infantsThe WA Kids Cancer Centre has secured $1.1 million in funding from the Medical Research Future Fund’s (MRFF) Paediatric Brain Cancer Research Stream 2 to develop more effective and less toxic treatments for rare brain cancers in infants.